Shots:

• The approval is based on P-III BLOCKSTONE study assessing Xofluza (baloxavir marboxil- 10/20mg) vs PBO in patients in household members aged ≥12yrs. who was living with someone with an influenza infection confirmed by a rapid influenza diagnostic test
• Result: The proportion of household members who developed influenza (1.9% vs 13.6%); well tolerated with no new safety signals identified
• Xofluza inhibits the cap-dependent endonuclease in the PA protein and is a single-dose oral treatment for influenza which is different from all other currently available antiviral treatments

 ­ Ref: Shionogi | Image: Businesswire